Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
' We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical development have been selected. In particular, we are pleased to share the long-term follow-up data from the TELLOMAK Phase 2 study, which underscores our continued commitment to advancing innovative therapies for patients," commented Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma.
ASCO abstract details:
Lacutamab
Abstract: 2522
Abstract Title: Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial
Session Type: Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Monday, June 2, 2025 – 1:30 – 4:30 PM CDT
Abstract: 2523
Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Long-term follow-up and translational data from the TELLOMAK phase 2 trial
Session Type: Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Monday, June 2, 2025 – 1:30 – 4:30 PM CDT
IPH4502
Abstract: TPS3159
Abstract Title: A phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors
Session Type: Poster Session
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Session Date and Time: Monday, June 2, 2025 – 1:30 – 4:30 PM CDT
Monalizumab (partnered with AstraZeneca)
Abstract: 8046
Abstract Title: Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.
Session Type: Poster Session
Session Title: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Date and Time: Saturday, May 31, 2025 – 1:30 – 4:30 PM CDT
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
This Analyst Says Lam Research (LRCX) is Among the Best AI Semiconductor Stocks to Buy on the Dip
Lam Research Corporation (NASDAQ:LRCX) is one of the . Lucas Downey from MoneyFlows talked about Lam Research Corporation (NASDAQ:LRCX) during a latest program on Schwab Network. He believes Lam Research is one of the top semiconductor stocks to buy on the dip. 'Semiconductors have been super hot, a name that I've owned for a number of years and continue to buy on dips, Lam Research. So, as AI continues to just gather steam and devices continue to get smaller, these are the types of companies that are going to win and they're going to lead. Just last quarter back in April, they gave earnings. They set their expectations well above the street. Those are the types of companies you want to be betting on on any type of pullback. And we know semiconductors can get very volatile, especially heading into earnings.' Appalaches Capital stated the following regarding Lam Research Corporation (NASDAQ:LRCX) in its Q1 2025 investor letter: 'We also initiated positions in ASML Holding N.V. (ASML) and Lam Research Corporation (NASDAQ:LRCX), companies that manufacture capital equipment for the semiconductor industry. You may be wondering if I have been 'red-pilled' by A.I. after being so iconoclastic to the trend just a year ago. Not quite. Despite all of the attention being given to Artificial Intelligence, the rest of the semiconductor industry, like memory and trailing-edge nodes, has been recovering out of a cyclical trough. Semiconductor foundries have additionally announced large increases to their capital expenditure budgets, which flow directly into the backlogs of companies like ASML and Lam. After a long period of consolidation, both operate in a highly consolidated industry structure with little to no competition. Both companies have smart and disciplined capital allocation, returning most of their cash flows to shareholders through large repurchase programs. While not thought of as traditional value stocks (despite having healthy free cash flow yields), I have a very favorable view of the industry broadly. While we acknowledge the potential of LRCX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Knightscope Closes Another $1.3M in New Sales Wins, Renewals & Expansions
SUNNYVALE, Calif., July 23, 2025--(BUSINESS WIRE)--Knightscope, Inc. (NASDAQ: KSCP), a leader in autonomous security robots and emergency communication devices, today announced that it has surpassed another $1.3 million in new contracts, including major client renewals, strategic expansions, and new sales wins nationwide. This growth underscores the sustained demand for smarter and more secured environments. Nationwide Emergency Communication Devices Growth Knightscope locked in major new wins in the aviation, casinos & gaming, higher education, parks & recreation, healthcare, and local government sectors with a substantial 834 brand-new Emergency Communication Devices (ECDs) bookings. This surge of new contracts underscores the broad confidence in Knightscope's life-saving communication technology. Autonomous Security Robot Demand is on the Rise Knightscope's Autonomous Security Robot (ASR) demand is on the rise. Several new K5 agreements have been secured in the commercial real estate, smart infrastructure, and casinos & gaming sectors, emphasizing Knightscope's expanding reach in physical security and public safety. Key Takeaways Growing public sector footprint – cities, states, and law enforcement agencies are amplifying their use of Knightscope technology, expanding their ECD purchases and extending Full-Service Maintenance (FSM) agreements, reflecting continued confidence in Knightscope's solutions. Higher education commitment – both public and private institutions are embracing new installations and renewing FSM agreements for substantial fleets of ECDs, underscoring the value we bring to campus safety. Renewals signal strong momentum – several ASR subscriptions were renewed across strategic sectors, including commercial real estate and casinos & gaming, highlighting sustained demand and customer loyalty. About Knightscope Knightscope is transforming public safety with cutting-edge robotics and AI technologies. From autonomous security robots to advanced detection systems, Knightscope is committed to building safer communities where you live, work, study and visit. Our long-term ambition is bold but simple: to make the United States of America the safest country in the world. Learn more about us at Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," "proposes" and similar expressions. Forward-looking statements contained in this press release and other communications include, but are not limited to, statements about the Company's goals, profitability, growth, prospects, reduction of expenses, and outlook. Although Knightscope believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks, uncertainties and other important factors that could cause actual results to differ materially from such forward-looking statements, including the factors discussed under the heading "Risk Factors" in Knightscope's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of the document in which they are contained, and Knightscope does not undertake any duty to update any forward-looking statements, except as may be required by law. View source version on Contacts Public Relations overwatch@ Knightscope, Inc. (650) 924-1025 ext. 6
Yahoo
14 minutes ago
- Yahoo
Analyst Explains How Microsoft (MSFT) Stock Can Reach $600
Microsoft Corp (NASDAQ:MSFT) is one of the . Brian Schwartz, Oppenheimer analyst, recently talked about Microsoft Corp (NASDAQ:MSFT) during a program on CNBC and explained his bullish case for the company. The analyst has a $600 price target for the stock, which shows a 17% upside potential from July 21 stock price. 'What's going to get Microsoft stock specifically to our price target is going to be upside potential that we think is going to exist from the earnings and their cash flow. As the spending ramps in the near term, we think that the earnings power could be 15% higher than what investors are currently thinking over the next 12 months from Microsoft. That combined with if they can maintain an accelerated growth within the core business, that too could drive a higher multiple for Microsoft.' Photo by Adam Nowakowski on Unsplash Mar Vista U.S. Quality Premier Strategy stated the following regarding Microsoft Corporation (NASDAQ:MSFT) in its second quarter 2025 investor letter: 'Microsoft Corporation (NASDAQ:MSFT) shares rebounded in calendar Q2 following a strong fiscal Q3 2025 (March quarter), driven by accelerating demand for AI-related Azure services. Robust second-half momentum, coupled with strong bookings as reflected in the Remaining Performance Obligation exceeding $300 billion (+33% year over year), helped ease investor concerns around enterprise IT spending and the long-term return potential of Microsoft's substantial AI infrastructure investments. While we acknowledge the potential of MSFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
